


# Degeneración del sistema nervioso central en “oldest old”: descripción de nuevas patologías y repercusión clínica de las mismas

**Novedades en el conocimiento de los Trastornos Cognitivos y del Comportamiento**




Alberto Rábano

Fundación CIEN, ISCIII, Madrid

Hospital Universitario La Paz,  
abril, 2023


## OECD demographic deficit

2000–2030




**Fig. 3. Demographic deficit in OECD member nations.** Observed and projected size of the incoming (20–24) and outgoing (60–64) working-age cohorts in OECD countries, 2000–2030. Source: OECD figures, Oxford Institute of Population Ageing, 2012.

## Top 50 Countries With the Largest Percentage of Older Adults



## Population pyramids, EU-27, 2019 and 2050 (% share of total population)



Note: all data as of 1 January. 2019: estimates and provisional. 2050: population according to the 2019 projections, baseline variant (EUROPOP2019).


Source: Eurostat (online data codes: demo\_pjangroup and proj\_19np)

# Age, Neuropathology, and Dementia


George M. Sawa, Ph.D., Stephen B. Wharton, F.R.C.Path., Paul G. Ince, M.D.,  
Gillian Forster, B.Sc., Fiona E. Matthews, Ph.D., and Carol Brayne, M.D.,  
for the Medical Research Council Cognitive Function and Ageing Study

N Engl J Med 2009;360:2302-09.  
Copyright © 2009 Massachusetts Medical Society.

## A Hippocampus



## B Neocortex



**Figure 1. Modeled and Observed Prevalence of Moderate or Severe Pathological Lesions According to Age.**

Persons who died with dementia (yellow) are compared with those who died without dementia (blue). Filled symbols represent the observed prevalence of moderate or severe pathological lesions, and I bars show the 95% confidence intervals. The solid and broken lines represent modeled prevalence values.

# Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study


Melissa E Murray, Neill R Graff-Radford, Owen A Ross, Ronald C Petersen, Ranjan Duara, Dennis W Dickson

Lancet Neurol 2011; 10: 785-96

Varones  
↓ edad

Mujeres  
↑ edad

Limbic predominant



Hippocampal sparing

Densidad de ONF en hipocampo

Densidad de ONF en isocórtex temporal

Hippocampal sparing AD    Typical AD    Limbic predominant AD

# Primary age-related tauopathy (PART)

Acta Neuropathol (2014) 128:755–766  
DOI 10.1007/s00401-014-1349-0

CONSENSUS PAPER

## Primary age-related tauopathy (PART): a common pathology associated with human aging

John F. Crary · John Q. Trojanowski · Julie A. Schneider · Jose F. Steven E. Arnold · Johannes Attems · Thomas G. Beach · Eileen F. Marla Gearing · Lea T. Grinberg · Patrick R. Hof · Bradley T. Hy Gabor G. Kovacs · David S. Knopman · Julia Koffler · Walter A. K Ann McKee · Thomas J. Montine · Melissa E. Murray · Janna H. Alberto Serrano-Pozo · Michael L. Shelanski · Thor Stein · Masal Juan C. Troncoso · Jean Paul Vonsattel · Charles L. White 3rd · T Masahito Yamada · Peter T. Nelson

Acta Neuropathol (2015) 129:749–756  
DOI 10.1007/s00401-015-1390-7

POSITION PAPER

## PART is part of Alzheimer disease

Charles Duyckaerts · Heiko Braak · Jean-Pierre Michel Goedert · Glenda Halliday · Manuela Neumann · Maria Grazia Spillantini · Markus Tolnay · Toshiki Uchihara

Acta Neuropathol  
DOI 10.1007/s00401-015-1407-2

CORRESPONDENCE

## PART, a distinct tauopathy, different from classical sporadic Alzheimer disease

Kurt A. Jellinger<sup>1</sup> · Irina Alafuzoff<sup>2</sup> · Johannes Attems<sup>3</sup> · Thomas G. Beach<sup>4</sup> · Nigel J. Cairns<sup>5</sup> · John F. Crary<sup>6</sup> · Dennis W. Dickson<sup>7</sup> · Patrick R. Hof<sup>8</sup> · Bradley T. Hyman<sup>9</sup> · Clifford R. Jack Jr.<sup>10</sup> · Gregory A. Jicha<sup>11</sup> · David S. Knopman<sup>12</sup> · Gabor G. Kovacs<sup>13</sup> · Ian R. Mackenzie<sup>14</sup> · Eliezer Masliah<sup>15,16</sup> · Thomas J. Montine<sup>17</sup> · Peter T. Nelson<sup>18</sup> · Frederick Schmitt<sup>11</sup> · Julie A. Schneider<sup>19,20</sup> · Albert Serrano-Pozo<sup>21</sup> · Dietmar R. Thal<sup>22</sup> · Jonathan B. Toledo<sup>23</sup> · John Q. Trojanowski<sup>23</sup> · Juan C. Troncoso<sup>24</sup> · Jean Paul Vonsattel<sup>6</sup> · Thomas Wisniewski<sup>25,26,27</sup>

Acta Neuropathol

**Table 1** Hypothetical correlation between PART and AD

	No AD/no PART	Asymptomatic PART	p-preAD	NFT-predominant Dementia (symptomatic PART)	Symptomatic AD
Aβ phase	0	0–2	1–5	0–2	3–5
Braak-NFT-stage	0	I–IV	0–VI	III, IV	III–VI
Degree of AD pathology	No AD	No or low AD	Low–high AD	No AD or low	Intermediate–high AD
Clinical signs of dementia or cognitive decline	No	No	No	Yes	Yes


PART vs. AD: symptomatic PART and symptomatic AD can be distinguished by Aβ pathology. Asymptomatic PART and p-preAD overlap in those cases with initial Aβ pathology (Aβ phases 1, 2)





# Four distinct trajectories of tau deposition identified in Alzheimer's disease


Jacob W. Vogel<sup>1</sup>✉, Alexandra L. Young<sup>2</sup>, Neil P. Oxtoby<sup>3,4</sup>, Ruben Smith<sup>5,6</sup>, Rik Ossenkoppele<sup>5,7</sup>, Olof T. Strandberg<sup>5</sup>, Renaud La Joie<sup>8</sup>, Leon M. Aksam<sup>3,9</sup>, Michel J. Grothe<sup>10,11</sup>, Yasser Iturria-Medina<sup>1</sup>, the Alzheimer's Disease Neuroimaging Initiative<sup>1</sup>, Michael J. Pontecorvo<sup>12</sup>, Michael D. Devous<sup>12</sup>, Gil D. Rabinovici<sup>8,13</sup>, Daniel C. Alexander<sup>3,4</sup>, Chul Hyong Lyoo<sup>14</sup>, Alan C. Evans<sup>1</sup> and Oskar Hansson<sup>5,15</sup>✉



Forum


Subtypes of Alzheimer's disease: questions, controversy, and meaning

Jacob W. Vogel<sup>1,2,\*</sup> and Oskar Hansson<sup>3,4,\*</sup>



# A matter of time: chronology of current neuropathological diagnostic guidelines

<b>2000</b>			<b>2011</b>		
<b>2001</b>			<b>2012</b>	NIA-AA	Vascular score
<b>2002</b>			<b>2013</b>	ALS	GGT
<b>2003</b>	Braak $\alpha$ -syn		<b>2014</b>	PART	
<b>2004</b>	AGD		<b>2015</b>		
<b>2005</b>			<b>2016</b>	VCING	ARTAG
<b>2006</b>			<b>2017</b>	DLB IV	
<b>2007</b>	FTLD		<b>2018</b>		
<b>2008</b>			<b>2019</b>	LATE-NC	
<b>2009</b>			<b>2020</b>		
<b>2010</b>			<b>2021</b>	LPC	CTE II



CONSENSUS PAPER

**National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach**




Thomas J. Montine · Creighton H. Phelps · Thomas G. Beach · Eileen H. Bigio · Nigel J. Cairns · Dennis W. Dickson · Charles Duyckaerts · Matthew P. Frosch · Eliezer Masliah · Suzanne S. Mirra · Peter T. Nelson · Julie A. Schneider · Dietmar Rudolf Thal · John Q. Trojanowski · Harry V. Vinters · Bradley T. Hyman

**Table 2** “ABC” score for AD neuropathologic change

“A”	Thal Phase for Aβ plaques [57]	“B”	Braak and Braak NFT stage [14,15]	“C”	NERAD neuritic plaque score [41]
0	0	0	None	0	None
1	1 or 2	1	I or II	1	Sparse
2	3	2	III or IV	2	Moderate
3	4 or 5	3	V or VI	3	Frequent

**Table 3** “ABC” score for level of AD neuropathologic change

AD neuropathologic change		B <sup>a</sup>		
A <sup>b</sup>	C <sup>c</sup>	0 or 1	2	3
0	0	Not <sup>d</sup>	Not <sup>d</sup>	Not <sup>d</sup>
1	0 or 1	Low	Low	Low <sup>e</sup>
	2 or 3 <sup>f</sup>	Low	<b>Intermediate</b>	Intermediate <sup>e</sup>
2	Any C	Low <sup>g</sup>	Intermediate	Intermediate <sup>e</sup>
	0 or 1	Low <sup>g</sup>	Intermediate	Intermediate <sup>e</sup>
3	0 or 1	Low <sup>g</sup>	Intermediate	Intermediate <sup>e</sup>
	2 or 3	Low <sup>g</sup>	Intermediate	High



Alzheimer’s disease neuropathological change: **A1 B2 C3**

# Staging and natural history of cerebrovascular pathology in dementia

2012

Neurology® 2012;78:1-1

V. Deramecourt, MD, PhD  
 J.Y. Slade, BSc  
 A.E. Oakley, MBiol  
 R.H. Perry, FRCPath  
 P.G. Ince, FRCPath  
 C.-A. Maurage, MD, PhD  
 R.N. Kalaria, FRCPath

Lóbulo frontal  
 Lóbulo temporal  
 (0-6)

Hipocampo  
 (0-4)


Ganglios basales  
 (0-4)

Score total ( $\Sigma$ )  
 (0-20)

Table 2 Staging of the cerebrovascular lesions

Score	Staging
<b>Frontal and temporal lobes</b>	
0	Normal appearance of brain, vessels, white matter, and cortex
I	Mild modification of vessel walls, perivascular spaces, or white matter
II	Moderate to severe but isolated modification of the vessel walls (arteriosclerosis or amyloid angiopathy), usually associated with hemosiderin deposits in the perivascular spaces
III	Moderate to severe perivascular space dilatations either in the deep or the juxtacortical white matter
IV	Moderate to severe myelin loss
V	Presence of cortical microinfarcts
VI	Presence of large infarcts
<b>Hippocampus</b>	
0	Normal appearance
I	Mild modification of vessel walls or perivascular spaces
II	Moderate to severe perivascular space dilatations
III	Presence of microinfarcts (usually in Ammon horn or the subiculum)
IV	Presence of large infarcts
<b>Basal ganglia</b>	
0	Normal appearance
I	Mild modification of vessel walls or perivascular spaces
II	Moderate to severe perivascular space dilatations
III	Presence of microinfarcts
IV	Presence of large infarcts
<b>Total vascular score</b>	
Frontal lobe + Temporal lobe + Hippocampus + Basal ganglia (/20)	

Figure 3 Distribution of the cerebrovascular lesions, example of the frontal lobe



## Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment



Olivia A. Skrobot,<sup>1</sup> Johannes Attems,<sup>2</sup> Margaret Esiri,<sup>3</sup> Tibor Hortobágyi,<sup>4,5</sup> James W. Ironside,<sup>6</sup> Rajesh N. Kalaria,<sup>2</sup> Andrew King,<sup>7</sup> George A. Lammie,<sup>8</sup> David Mann,<sup>9</sup> James Neal,<sup>10</sup> Yoav Ben-Shlomo,<sup>11</sup> Patrick G. Kehoe<sup>1</sup> and Seth Love<sup>1</sup>

### Likelihood that cerebral vascular disease contributed to cognitive impairment

One or more large (> 10 mm) subcortical cerebral infarcts

Moderate or severe occipital leptomeningeal CAA

Moderate or severe occipital white matter arteriolosclerosis



	Low (<50%)			Moderate (50-80%)		High (>80%)		
One or more large (> 10 mm) subcortical cerebral infarcts	-	-	-	+	-	+	+	+
Moderate or severe occipital leptomeningeal CAA	-	+	-	-	+	+	-	+
Moderate or severe occipital white matter arteriolosclerosis	-	-	+	-	+	-	+	+


**Figure 1** VCING model estimating the likelihood that cerebrovascular disease contributed to cognitive impairment.

Combinations of the three main determinants—at least one large (> 10 mm diameter) infarct, moderate/severe occipital leptomeningeal CAA, and moderate/severe arteriolosclerosis in the occipital white matter—are used to assign a low, intermediate or high likelihood that cerebrovascular disease contributed to cognitive impairment in an individual case. Scale bars in the *top*, *middle* and *bottom* photomicrographs represent 1 mm, 250 μm and 100 μm, respectively.



## Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study

Johannes Attems<sup>1</sup> · Jon B. Toledo<sup>2,3</sup> · Lauren Walker<sup>1</sup> · Ellen Gelpi<sup>4,5</sup> · Steve Gentleman<sup>6</sup> · Glenda Halliday<sup>7</sup> · Tibor Hortobagyi<sup>8,9,10,11</sup> · Kurt Jellinger<sup>12</sup> · Gabor G. Kovacs<sup>13,14</sup> · Edward B. Lee<sup>3</sup> · Seth Love<sup>15</sup> · Kirsty E. McAleese<sup>1</sup> · Peter T. Nelson<sup>16</sup> · Manuela Neumann<sup>17,18</sup> · Laura Parkkinen<sup>19,20</sup> · Tuomo Polvikoski<sup>1</sup> · Beata Sikorska<sup>21</sup> · Colin Smith<sup>22</sup> · Lea Tenenholz Grinberg<sup>23,24</sup> · Dietmar R. Thal<sup>25</sup> · John Q. Trojanowski<sup>3</sup> · Ian G. McKeith<sup>1</sup>




Patología de Lewy cortical  
(alfa-sinucleína)


### Lewy Pathology Consensus Criteria (LPC)

Category of LP	OB	Amy.	dmX or SN (1)	MTL or Cing. (1)	Fr. or Pa. ctx (1)
Olfactory only	+	-	-	-	-
Amygdala predominant	-/+	+	-	-	-
Brainstem predominant	-/+	-/+	+	-	-
Limbic	-/+	-/+	-/+	+	-
Neocortical	-/+	-/+	-/+	-/+	+


### Olfactory only




### Amygdala predominant




### Brainstem predominant



### Limbic



### Neocortical



**REVIEW**
**Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report**

Peter T. Nelson,<sup>1</sup>  Dennis W. Dickson,<sup>2</sup> John Q. Trojanowski,<sup>3</sup> Clifford R. Jack Jr.,<sup>4</sup> Patricia A. Boyle,<sup>5</sup> Konstantinos Arfanakis,<sup>5,6</sup> Rosa Rademakers,<sup>2</sup> Irina Alafuzoff,<sup>7</sup> Johannes Attems,<sup>8</sup> Carol Brayne,<sup>9</sup> Ian T.S. Coyle-Gilchrist,<sup>9</sup> Helena C. Chui,<sup>10</sup> David W. Fardo,<sup>1</sup> Margaret E. Flanagan,<sup>11</sup> Glenda Halliday,<sup>12</sup> Suvi R.K. Hokkanen,<sup>9</sup> Sally Hunter,<sup>9</sup> Gregory A. Jicha,<sup>1</sup> Yuriko Katsumata,<sup>1</sup> Claudia H. Kawas,<sup>13</sup> C. Dirk Keene,<sup>14</sup> Gabor G. Kovacs,<sup>15</sup> Walter A. Kukull,<sup>14</sup> Allan I. Levey,<sup>16</sup> Nazanin Makkejad,<sup>6</sup> Thomas J. Montine,<sup>17</sup> Shigeo Murayama,<sup>18</sup> Melissa E. Murray,<sup>2</sup> Sukriti Nag,<sup>5</sup> Robert A. Rissman,<sup>19</sup>  William W. Seeley,<sup>20</sup> Reisa A. Sperling,<sup>21</sup> Charles L. White III,<sup>22</sup> Lei Yu<sup>5</sup> and Julie A. Schneider<sup>5</sup>

## Limbic-predominant age-related TDP-43 encephalopathy (LATE)

LATE-NC

Stages 0 → 3

### B LATE-NC related stages based on anatomic distribution of TDP-43 pathology


Simplified staging of TDP-43 proteinopathy* for routine LATE-NC diagnosis (consensus recommendation)		Josephs TDP-43 proteinopathy staging (KA Josephs et al, 2013)		Rush University TDP-43 proteinopathy staging (S Nag et al, 2017)	
0	None	0	None	0	None
1	Amygdala	1	Amygdala	1	Amygdala
2	Hippocampus	2	Entorhinal cortex, subiculum	2	Entorhinal cortex, CA1
		3	Dentate, Occipitotemporal cortex	3	Anterior temporal cortex
		4	Insula, Inf temporal cortex	4	Midtemporal and orbitofrontal cortex
		5	Inf olive, midbrain		
3	Middle frontal gyrus (MFG)	6	Basal ganglia, MFG	5	MFG

\*-Any TDP-43 proteinopathy is seen in that anatomic region



Esclerosis del  
hipocampo

TDP-43






H/E

RESEARCH ARTICLE


# A novel histological staging of hippocampal sclerosis that is evident in gray matter loss in vivo

Diana Ortega-Cruz<sup>1,2</sup> | Alicia Uceda-Heras<sup>2,3</sup> | Juan Eugenio Iglesias<sup>4,5</sup> |  
María Ascensión Zea-Sevilla<sup>2</sup> | Bryan Strange<sup>1,2</sup> | Alberto Rabano<sup>2</sup>





# Argyrophilic grain disease


Gallyas



Tau AT8



Rábano et al., 2014



Saito et al., 2004

*Acta Neuropathol.* 2016 January ; 131(1): 87–102. doi:10.1007/s00401-015-1509-x.

## Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy

*A full list of authors and affiliations appears at the end of the article.*

Kovacs et al. *Acta Neuropathologica Communications* (2018) 6:50  
<https://doi.org/10.1186/s40478-018-0552-y>

Acta Neuropathologica  
Communications



RESEARCH

Open Access



## Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain

Gabor G. Kovacs<sup>1,2\*</sup>, Sharon X. Xie<sup>3</sup>, John L. Robinson<sup>2</sup>, Edward B. Lee<sup>2</sup>, Douglas H. Smith<sup>4</sup>, Theresa Schuck<sup>2</sup>, Virginia M.-Y. Lee<sup>2</sup> and John Q. Trojanowski<sup>2\*</sup>



**Fig. 3** Heatmap of severity scores of subpial (a), white matter (b) and grey matter (c) ARTAG in the cohort of non-FTLD tauopathies. The more dark colours reflect higher severity scores

Perspective

## Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development

Gil D. Rabinovici<sup>a</sup>, Maria C. Carrillo<sup>b</sup>, Mark Forman<sup>c</sup>, Susan DeSanti<sup>d</sup>, David S. Miller<sup>e</sup>, Nicholas Kozauer<sup>f</sup>, Ronald C. Petersen<sup>g</sup>, Christopher Randolph<sup>h,i</sup>, David S. Knopman<sup>g</sup>, Eric E. Smith<sup>j</sup>, Maria Isaac<sup>k</sup>, Niklas Mattsson<sup>l,m</sup>, Lisa J. Bain<sup>n</sup>, James A. Hendrix<sup>b,\*</sup>, John R. Sims<sup>o</sup>

*Alzheimers Dement.* 2017 June ; 13(6): 654–662. doi:10.1016/j.jalz.2016.09.015.

## Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample

Willa D. Brenowitz<sup>1</sup>, Rebecca A. Hubbard<sup>2</sup>, C. Dirk Keene<sup>3</sup>, Stephen E. Hawes<sup>4</sup>, W.T. Longstreth Jr<sup>1,5</sup>, Randy L. Woltjer<sup>6</sup>, and Walter A. Kukull<sup>1</sup>

<sup>1</sup>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, Washington, USA

*Acta Neuropathol.* 2018 September ; 136(3): 377–388. doi:10.1007/s00401-018-1872-5.

## Non-Alzheimer's contributions to dementia and cognitive resilience in The 90+ Study

John L. Robinson<sup>1</sup>, Maria M. Corrada<sup>2</sup>, Gabor G. Kovacs<sup>1,3</sup>, Myrna Dominique<sup>1</sup>, Carrie Caswell<sup>4</sup>, Sharon X. Xie<sup>4</sup>, Virginia M.-Y. Lee<sup>1</sup>, Claudia H. Kawas<sup>5</sup>, and John Q. Trojanowski<sup>1</sup>



## Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease

Salvatore Spina<sup>1,†</sup>, Renaud La Joie<sup>1,†</sup>, Cathrine Petersen<sup>1</sup>, Amber L. Nolan<sup>1</sup>, Deion Cuevas<sup>1</sup>, Celica Cosme<sup>1</sup>, Mackenzie Hepker<sup>1</sup>, Ji-Hye Hwang<sup>1</sup>, Zachary A. Miller<sup>1</sup>, Eric J. Huang<sup>2</sup>, Anna M. Karydas<sup>1</sup>, Harli Grant<sup>1</sup>, Adam L. Boxer<sup>1</sup>, Maria Luisa Gorno-Tempini<sup>1</sup>, Howard J. Rosen<sup>1</sup>, Joel H. Kramer<sup>1</sup>, Bruce L. Miller<sup>1</sup>, William W. Seeley<sup>1,2</sup>, Gil D. Rabinovici<sup>1,3</sup> and Lea T. Grinberg<sup>1,2</sup>

## Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

John L. Robinson<sup>1,2,3,4</sup>, Edward B. Lee<sup>1,2,3,4</sup>, Sharon X. Xie<sup>1,2,3,4,5</sup>, Lior Rennert<sup>1,2,3,4,5</sup>, EunRan Suh<sup>1,2,3,4</sup>, Colin Bredenberg<sup>1,2,3,4</sup>, Carrie Caswell<sup>1,2,3,4,5</sup>, Viviana M. Van Deerlin<sup>1,2,3,4</sup>, Ning Yan<sup>1,2,3,4,6</sup>, Ahmed Yousef<sup>1,2,3,4</sup>, Howard I. Hurtig<sup>1,2,3,7</sup>, Andrew Siderowf<sup>1,2,3,7</sup>, Murray Grossman<sup>1,2,3,7,8</sup>, Corey T. McMillan<sup>7,8</sup>, Bruce Miller<sup>9</sup>, John E. Duda<sup>3,10</sup>, David J. Irwin<sup>1,2,3,7,8</sup>, David Wolk<sup>1,2,3,7,8,11</sup>, Lauren Elman<sup>3,7</sup>, Leo McCluskey<sup>3,7</sup>, Alice Chen-Plotkin<sup>1,2,3,7</sup>, Daniel Weintraub<sup>2,3,12</sup>, Steven E. Arnold<sup>1,3</sup>, Johannes Bretschneider<sup>14</sup>, Virginia M.-Y. Lee<sup>1,2,3,4,7</sup> and John Q. Trojanowski<sup>1,2,3,4,7</sup>


# Heterogeneidad patológica y comorbilidad en demencia



- Patología de tipo Alzheimer
- Patología cerebrovascular
- Patología de tipo Lewy
- Limbic-predominant age-related TDP-43 encephalopathy (LATE)
- Aging-related tau astroglipathy (ARTAG)
- Enfermedad de granos argirófilos
- Otras patologías




<b>N</b>	167
<b>Sex</b>	79% female
<b>T in CAFRS (mths)</b>	52.9 (38.6)
<b>Age at onset</b>	75.4 (7.3)
<b>Age at death</b>	87.2 (6.5)
<b>Survival time</b>	11.9 (4.4)
<b>PMI (hrs.)</b>	4.5 (2.1)
<b>APOE e4</b>	45.2%
<b>High ADNC</b>	75.8%
<b>High vascular path.</b>	54.5%
<b>Lewy path. (LPC&gt;1)*</b>	37.8%
<b>LATE (HS)</b>	71.2% (45.2%)
<b>ARTAG</b>	52.7%
<b>AGD</b>	12%

## Main neuropathological diagnosis





# Vallecas Alzheimer's Study



- Alzheimer' pathology (Braak stage 0 – 6)
- Cerebrovascular pathology (0 – 5)
- Lewy type pathology (0 – 6)
- TDP-43 pathology (LATE) (0 – 3)
- ARTAG (0 – 1)
- Argyrophilic grain disease (0 – 3)

# Normative Cognitive Decline in Old Age

Robert S. Wilson, PhD <sup>1,2,3</sup> Tianhao Wang, PhD,<sup>1,2</sup> Lei Yu, PhD <sup>1,2</sup>  
David A. Bennett, MD,<sup>1,2</sup> and Patricia A. Boyle, PhD<sup>1,3</sup>






FIGURE 1: Crude trajectories of change in global cognition in 100 randomly selected participants.



**OPEN Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology**

David X. Thomas<sup>1,3</sup>, Sumali Bajaj<sup>2,3</sup>, Kevin McRae-McKee<sup>2</sup>, Christoforos Hadjichrysanthou<sup>2</sup>, Roy M. Anderson<sup>2</sup> & John Collinge<sup>1</sup>

SCIENTIFIC REPORTS | (2020) 10:14579




RESEARCH

Open Access

# Neuropathology of supercentenarians - four autopsy case studies



Masaki Takao<sup>1,4\*</sup>, Nobuyoshi Hirose<sup>2</sup>, Yasumichi Arai<sup>2</sup>, Ban Mihara<sup>3</sup> and Masaru Mimura<sup>4</sup>




**Fig. 2** Coronal sections at the basal ganglia and hippocampus level. Cortical ribbons and cerebral white matter are well-preserved. Small cortical infarct in Case 1 (a). **a** Case 1, **(b)** Case 2, **(c)** Case 3, **(d)** Case 4. Bar = 1 cm


**Table 1** Patient demographics and summary of neuropathological analyses

	Case 1 (111 yo)	Case 2 (111 yo)	Case 3 (114 yo)	Case 4 (110 yo)
Sex	Female	Female	Female	Female
Past medical history	HT-, DM-	HT-, DM-	HT-, DM-	HT+, DM-
Clinical condition before death	Clear communication, wheel chair	No dementia	Clear communication, wheel chair	Almost clear communication, wheel chair
Barthel index	10	60	90	20
CDR	0.5	NA	0	NA
MMSE	NA due to refusal Age 106	15 Age 106	22 Age 108 MMSE was 18 at age 113 and 114	NA Age 109
Cause of death	Heart failure	Renal failure	Senility	Sepsis
APOE	2/3	2/3	3/3	3/3
Brain weight (fresh)	460 (left hemisphere)	925	1,015	1,115
Atrophy	F, T	F, T	F, T	T
A-beta, Thal phase	3 (A2)	3 (A2)	1 (A1)	2 (A1)
NFT stage (AT8) (Braak)	III (B2)	IV (B2)	III (B2)	IV (B2)
Neuritic plaques (CERAD)	Moderate (C2)	Moderate (C2)	Sparse (C1)	Moderate (C2)
CAA	None	None	None	Mild
AD pathological changes (NIA-Reagan)	Intermediate	Intermediate	Unclassified	Intermediate
AD pathological changes (NIA-AA)	Intermediate	Intermediate	Low PART possible	Intermediate
ARTAG	Subpial, subependymal, gray matter, white matter, perivascular	Subpial, gray matter, white matter	Subpial, gray matter, white matter	Subpial, subependymal, gray matter, perivascular
Arteriolosclerosis	Mild to moderate	Mild to moderate	Mild to moderate	Mild to moderate
White matter rarefaction	Moderate	Mild	Mild	Moderate
État criblé (basal ganglia and thalamus)	Moderate	Severe	Severe	Moderate
Vascular brain injury	Multiple cortical infarcts	None	None	None
Alpha-synuclein pathology	None	None	None	None
TDP-43 pathology	Present, subiculum, PHG	Present, subiculum, PHG	Uncus, sparse	Uncus, sparse
Hippocampal sclerosis	None	None	None	None
Hirano bodies/GVD (Hippocampus)	Present/present	Present/present	Present/present	Present/present

## The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia

Emma Nichols, PhD,<sup>a,\*</sup> Richard Merrick, MSc,<sup>b</sup> Simon I Hay, Prof, FMedSci,<sup>a</sup> Dibya Himali, MS,<sup>c</sup> Jayandra J Himali, PhD,<sup>c,d,e,f</sup> Sally Hunter, MSc,<sup>b</sup> Hannah A D Keage, Prof, PhD,<sup>g</sup> Caitlin S Latimer, MD,<sup>h</sup> Matthew R Scott, BA,<sup>c,f</sup> Jaimie D Steinmetz, PhD,<sup>a</sup> Jamie M Walker, PhD,<sup>i</sup> Stephen B Wharton, Prof, PhD,<sup>j</sup> Crystal D Wiedner, PhD,<sup>d</sup> Paul K Crane, Prof, MD,<sup>k</sup> C Dirk Keene, Prof, MD,<sup>h</sup> Lenore J Launer, PhD,<sup>l</sup> Fiona E Matthews, Prof, PhD,<sup>m</sup> Julie Schneider, Prof, MD,<sup>n,o</sup> Sudha Seshadri, Prof, MD,<sup>c,d,e</sup> Lon White, MD,<sup>p</sup> Carol Brayne, Prof, MD,<sup>b</sup> and Theo Vos, Prof, PhD<sup>a</sup>





# Gracias!



Web: <http://bt.fundacioncien.es/>

Twitter: [@banco\\_tx\\_CIEN](https://twitter.com/banco_tx_CIEN)